	US 12,187,774 B2
	Heterodimeric Relaxin fusions and uses thereof
Isabelle Sermadiras, Cambridge (GB); Monika Anna Papworth, Cambridge (GB); Judy Christiane Paterson, Cambridge (GB); Esther Marie Martin, Cambridge (GB); and Peng Ke, Cambridge (GB)
Assigned to MEDIMMUNE LIMITED, Cambridge (GB)
Filed by MEDIMMUNE LIMITED, Cambridge (GB)
Filed on Jul. 1, 2023, as Appl. No. 18/346,205.
Application 18/346,205 is a division of application No. 17/348,825, filed on Jun. 16, 2021, granted, now 11,795,205.
Claims priority of provisional application 63/040,250, filed on Jun. 17, 2020.
Prior Publication US 2024/0025958 A1, Jan. 25, 2024
Int. Cl. C07K 14/64 (2006.01); A61K 38/22 (2006.01); A61P 9/04 (2006.01); C07K 19/00 (2006.01); C12N 15/85 (2006.01); A61K 47/68 (2017.01)

CPC C07K 14/64 (2013.01) [A61K 38/2221 (2013.01); A61P 9/04 (2018.01); C07K 19/00 (2013.01); C12N 15/85 (2013.01); A61K 47/6811 (2017.08); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01)]

6 Claims

1. A nucleic acid molecule encoding a heterodimeric fusion comprising:

(i) a polypeptide according to SEQ ID NO: 11; and

(ii) a polypeptide according to SEQ ID NO: 20;

wherein SEQ ID NO: 11 comprises a first heterodimerisation domain connected to a Relaxin A chain polypeptide;

wherein SEQ ID NO: 20 comprises a second heterodimerisation domain connected to a Relaxin B chain polypeptide;

wherein the first heterodimerisation domain heterodimerises with the second heterodimerisation domain, and wherein the heterodimeric fusion has Relaxin activity.